James D Hoeschele
Overview
Explore the profile of James D Hoeschele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbanente A, Papadia P, Di Cosola A, Pacifico C, Natile G, Hoeschele J, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000496
It is generally accepted that adjacent guanine residues in DNA are the primary target for platinum antitumor drugs and that differences in the conformations of the Pt-DNA adducts can play...
2.
Gandin V, Hoeschele J, Margiotta N
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175624
The year 2023 marks the 45th year since FDA approval of cisplatin as an anticancer drug, and, at present, it is widely used against a spectrum of human tumors, including...
3.
Barbanente A, Gandin V, Ceresa C, Marzano C, Ditaranto N, Hoeschele J, et al.
Int J Mol Sci
. 2022 Jul;
23(13).
PMID: 35806087
Kiteplatin, [PtCl(-1,4-DACH)] (DACH = diaminocyclohexane), contains an isomeric form of the oxaliplatin diamine ligand -1,2-DACH and has been proposed as a valuable drug candidate against cisplatin- and oxaliplatin-resistant tumors, in...
4.
Papadia P, Gandin V, Barbanente A, Ruello A, Marzano C, Micoli K, et al.
RSC Adv
. 2022 May;
9(56):32448-32452.
PMID: 35529760
A new family of anticancer compounds has been derived from oxaliplatin by inserting a double-bond between carbons 4 and 5 of the 1,2-diaminocyclohexane ring. Testing against a panel of human...
5.
Papadia P, Barbanente A, Ditaranto N, Hoeschele J, Natile G, Marzano C, et al.
Dalton Trans
. 2021 Oct;
50(43):15655-15668.
PMID: 34673864
Six enantiomerically pure, oxaliplatin-like, platinum compounds (two platinum(II) and four platinum(IV)), all containing unsaturated cyclic diamine -1,2-diamino-4-cyclohexene (DACHEX) as a substitute for the -1,2-diaminocyclohexane used in oxaliplatin, were investigated. The...
6.
Barbanente A, Iacobazzi R, Azzariti A, Hoeschele J, Denora N, Papadia P, et al.
Molecules
. 2021 Jul;
26(11).
PMID: 34200051
Two new Pt(II)-pyrophosphato complexes containing the carrier ligands -1,3-diaminocyclohexane (-1,3-DACH) and -1,2-diamine-4-cyclohexene (1,2-DACHEX), variants of the 1,2-diaminocyclohexane ligand present in the clinically used Pt-drug oxaliplatin, have been synthesized with the...
7.
Hoeschele J, Kasparkova J, Kostrhunova H, Novakova O, Pracharova J, Pineau P, et al.
J Biol Inorg Chem
. 2020 Aug;
25(6):913-924.
PMID: 32851480
The search for more effective platinum anticancer drugs has led to the design, synthesis, and preclinical testing of hundreds of new platinum complexes. This search resulted in the recognition and...
8.
Papadia P, Micoli K, Barbanente A, Ditaranto N, Hoeschele J, Natile G, et al.
Int J Mol Sci
. 2020 Apr;
21(7).
PMID: 32230896
Six platinum(IV) compounds derived from an oxaliplatin analogue containing the unsaturated cyclic diamine -1,2-diamino-4-cyclohexene (DACHEX), in place of the 1,2-diaminocyclohexane, and a range of axial ligands, were synthesized and characterized....
9.
Canil G, Braccini S, Marzo T, Marchetti L, Pratesi A, Biver T, et al.
Dalton Trans
. 2019 Jun;
48(29):10933-10944.
PMID: 31165118
The use of Pt(iv) complexes as potential anticancer drugs is attractive, because they have higher stability and less side effects than Pt(ii) compounds. Moreover, some Pt(iv) complexes can also be...
10.
Savino S, Marzano C, Gandin V, Hoeschele J, Natile G, Margiotta N
Int J Mol Sci
. 2018 Jul;
19(7).
PMID: 30011897
Platinum(II) drugs are activated intracellularly by aquation of the leaving groups and then bind to DNA, forming DNA adducts capable to activate various signal-transduction pathways. Mostly explored in recent years...